CA
NZ
UK
AU
IND
US
Vertex Pharmaceuticals (NASDAQ: VRTX) lifted its full‑year 2026 revenue outlook to a $13.1‑$13.2 billion range, a 1 % increase from the previous $12.95‑$13.1 billion corridor.
Viemed Healthcare's revenue increased 23.9% to $78.1 million, driven by growth in ventilator and PAP therapy patients, and the company raised its full-year guidance. This increase in revenue is significant for investors as it demonstrates the company's ability to expand its patient base and …
Stoke Therapeutics (NASDAQ: STOK) posted a cash balance of $420.0 million, up from $354.3 million, after securing $65.7 million in an at‑the‑market sale. The infusion of liquidity pushes the company's runway out to early 2028, ensuring it can sustain the costly development and potential …
Oncology Institute, Inc. has rebranded itself as Starling Oncology, effective immediately, marking a key moment in its corporate identity. The company will now trade on the Nasdaq under the new ticker symbol "STLN," replacing "TOI." This name change comes as part of a broader …
Oric Pharmaceuticals (NASDAQ: ORIC) increased its cash, cash equivalents, and short‑term investments to $387.6 million, a level that management expects to sustain operations through the second half of 2028. The quarter’s earnings per share fell short of analyst expectations, indicating a modest miss. The …
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is facing a class action deadline for investors to act by September 28, 2026. This lawsuit arises from allegations of misleading sales practices that inflated reported revenues. The outcome could significantly affect investor recovery and market confidence.Key HighlightsPRCT shares …
SenesTech (NASDAQ: SNES) reported that its active online subscription base more than doubled in the second quarter of 2026, propelling e‑commerce sales up 186% from the prior quarter. The rapid expansion helped the company post earnings per share of $‑0.31, outpacing the consensus forecast …
SI-BONE (NASDAQ: SIBN) reported adjusted EBITDA of $2.8 million for the quarter ended June 30, a 178 % increase from the same period a year earlier and its first positive EBITDA figure. Revenue climbed to $56.0 million, up 15.2% YoY, while the net loss …
Lipocine Inc. (NASDAQ: LPCN) expanded its Board of Directors by appointing Michael Grissinger, effective August 3, 2026. This change comes as the company continues to face harsh market conditions, with year-to-date declines of 74% in its share price. Grissinger's extensive experience in pharmaceutical licensing …
Revenue contracted 27.6% year‑over‑year to $76.4 million, reflecting a steep decline in the number of independent coaches. Despite the revenue dip, average revenue per coach surged 41.0% to $6,529, underscoring a shift toward higher‑margin, productivity‑focused operations. The earnings surprise and coach‑level gains together paint …
Please wait processing your request...